ArticleScientific reports2015
Structural and Physical Basis for Anti-IgE Therapy.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 66 citations in OpenAlex.
- Toward personalized prediction: a multicenter machine learning model for omalizumab response duration in moderate-to-severe perennial allergic rhinitis.Frontiers in allergy · 2026Article
- Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte-Associated Gene Regulation.Immunity, inflammation and disease · 2025Article
- Biomarker understanding first lessons from drug development for IgA-driven autoimmune and fibrotic diseases.Cambridge prisms. Precision medicine · 2025Review
- Abrogation and homeostatic restoration of IgE responses by a universal IgE allergy CTL vaccine-The three signal self/non-self/self (S/NS/S) theory.Immunology · 2024Article
- Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes.Acta dermato-venereologica · 2024Article
- Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.Current allergy and asthma reports · 2023Review
- Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients-A Retrospective Study.Vaccines · 2022Article
- Efficient Strategy to Design Protease Inhibitors: Application to Enterovirus 71 2A Protease.ACS bio & med chem Au · 2022Article
- Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.International journal of molecular sciences · 2022Review
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
- Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology.Journal of asthma and allergy · 2022Article
- Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.Acta crystallographica. Section F, Structural biology communications · 2020Article
- Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.Drug design, development and therapy · 2020Review
- Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.Frontiers in immunology · 2020Article
- The use of biologics in children with allergic rhinitis and chronic rhinosinusitis: Current updates.Pediatric investigation · 2019Review
- Biological therapies for atopic dermatitis: An update.Experimental and therapeutic medicine · 2019Review
- New treatment directions in food allergy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Review
- Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.The Journal of biological chemistry · 2017Article
- Oral immunotherapy for food allergy.Seminars in immunology · 2017Review
- Critical and direct involvement of the CD23 stalk region in IgE binding.The Journal of allergy and clinical immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab, an anti-IgE antibody, used to treat severe allergic asthma and chronic idiopathic urticaria, binds to IgE in blood or membrane-bound on B lymphocytes but not to IgE bound to its high (FcεRI) or low (CD23) affinity receptor. Mutagenesis studies indicate overlapping FcεRI and omalizumab-binding sites in the Cε3 domain, but crystallographic studies show FcεRI and CD23-binding sites that are far apart, so how can omalizumab block IgE from binding both receptors? We report a 2.42-Å omalizumab-Fab structure, a docked IgE-Fc/omalizumab-Fab structure consistent with available experimental data, and the free energy contributions of IgE residues to binding omalizumab, CD23, and FcεRI. These results provide a structural and physical basis as to why omalizumab cannot bind receptor-bound IgE and why omalizumab-bound IgE cannot bind to CD23/FcεRI. They reveal the key IgE residues and their roles in binding omalizumab, CD23, and FcεRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.